Poolbeg to present at Master Investor Show, BioTrinity & Participate in a Panel Discussion at LSX World Congress 27 March 2025 – Poolbeg Pharma (AIM: POLB, ‘Poolbeg’ or the ‘Company’), a clinical-stage biopharmaceutical company focussed on the development of innovative medicines to address unmet medical needs, announces that CEO, Jeremy Skillington, will be participating in the following leading industry […]
All doses of POLB 001 significantly reduced clinically observed Cytokine Release Syndrome scores POLB 001 treatment showed statistically significant reductions in key cytokines Positive results reinforce the use case for POLB 001 in the prevention and treatment of cancer immunotherapy-induced CRS 9 December 2024 – Poolbeg Pharma (AIM: POLB, ‘Poolbeg’ or the ‘Company’), a clinical-stage biopharmaceutical company focused […]
Optimum Client’s Win Big at LSX European Lifestars Awards! Congratulations to Optimum’s clients – Asceneuron SA, Calliditas Therapeutics, DISCO Pharmaceuticals GmbH, Sofinnova Partners portfolio company Moon Surgical, Myricx Bio, and Novo Holdings, all of whom took home LSX European Lifestars awards! Plus, a special moment for Optimum’s Zoe Bolt who presented the award for Private […]
Further strengthens Poolbeg’s robust intellectual property portfolio 20 November 2024- Poolbeg Pharma (AIM: POLB, ‘Poolbeg’ or the ‘Company’), a clinical-stage biopharmaceutical company focused on the development and commercialisation of innovative medicines targeting diseases with a high unmet medical need, announces that the US Patent Office has notified the Company of its official decision to grant Poolbeg’s US Immunomodulator I […]
POLB 001 Reduces Cytokine Release Syndrome (CRS) in an in vivo animal model Positive results reinforce POLB 001’s potential in the prevention and treatment of cancer immunotherapy-induced CRS ASH is the world’s premier conference focussing on haematological malignancies 6 November 2024 – Poolbeg Pharma (AIM: POLB, ‘Poolbeg’ or the ‘Company’), a clinical-stage biopharmaceutical company focussed on the development […]
